Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

T2705

Sigma-Aldrich

Topotecan hydrochloride hydrate

≥98% (HPLC and enzymatic), powder, topoisomerase I inhibitor

Synonyme(s) :

9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin hydrochloride hydrate, NSC-609669 hydrochloride hydrate, SKF-104864A hydrochloride hydrate, hycamptamine hydrochloride hydrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H23N3O5 · xHCl · yH2O
Numéro CAS:
123948-87-8
Poids moléculaire :
421.45 (anhydrous free base basis)
Numéro MDL:
MFCD00870670
Code UNSPSC :
12352200
ID de substance PubChem :
329826724
Nomenclature NACRES :
NA.77

Nom du produit

Topotecan hydrochloride hydrate, ≥98% (HPLC and enzymatic)

Niveau de qualité

100

Essai

≥98% (HPLC and enzymatic)

Forme

powder

Conditions de stockage

desiccated
protect from light

Couleur

yellow

Solubilité

DMSO: ≥20 mg/mL

Auteur

GlaxoSmithKline

Température de stockage

−20°C

InChI

1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1

Clé InChI

UCFGDBYHRUNTLO-QHCPKHFHSA-N

Informations sur le gène

human ... TOP1MT(116447)

Application

Topotecan has been used as a positive control for the identification and analysis of HIF-1α and VEGF inhibitors in human glioma cells under hypoxic conditions1. It has also been used for in vitro apoptosis assays in PA317 cells2.

Actions biochimiques/physiologiques

Topotecan is a topoisomerase I inhibitor and an apoptosis inducer. It is a potent antineoplastic agent.

Caractéristiques et avantages

This compound is a featured product for ADME Tox and Apoptosis research. Discover more featured ADME Tox and Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Notes préparatoires

This product is soluble in water, however, the concentration has not been determined. Various sources state this chemical can be solubilized in water at greater than 1 mg/mL.
Topotecan hydrochloride hydrate is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H340,H361d

Classification des risques

Muta. 1B - Repr. 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
115M4703V
035M47101V
052M4728V
091M4704V
010M47487

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Ian F King et al.
Nature, 501(7465), 58-62 (2013-09-03)
Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor
ChunLei Li et al.
International journal of pharmaceutics, 443(1-2), 17-25 (2013-01-16)
Repeated injection of pegylated liposomes could elicit the disappearance of long-circulating characteristic, referred to as "accelerated blood clearance phenomenon." ABC phenomenon typically occurs when entrapped drugs are not cytotoxic, but recently it was reported that multiple doses of pegylated liposomal
Kaleem Ashraf et al.
Pediatric blood & cancer, 60(10), 1636-1641 (2013-05-08)
Reports of responses and toxicities of salvage therapies for relapsed neuroblastoma are rare and often confounded by effects of additional treatments. Our objective was to describe the outcomes and toxicities for a topotecan and cyclophosphamide (TOPO/CTX) regimen for first relapse
Israel Zighelboim et al.
Gynecologic oncology, 130(1), 64-68 (2013-04-18)
We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior
Jerec W Ricci et al.
Molecular cancer therapeutics, 15(12), 2853-2862 (2016-09-28)
Chemotherapeutic resistance remains a challenge in the treatment of ovarian carcinoma, especially in recurrent disease. Despite the fact that most patients with newly diagnosed tumors attain complete remission following cytoreductive surgery and chemotherapy, ovarian carcinoma has a recurrence rate that
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique